Background. A patient with sarcoidosis may be resistant to corticosteroid therapy. This may be because corticosteroids are ineffective in relieving the symptoms/dysfunction of a patient with sarcoidosis. Lack of response to treatment is not a rare phenomenon and requires the development of new diagnostic criteria and the search for alternative methods of treatment.

The aim of the work is to develop new prognostic criteria corticosteroid-resistant Lung Sarcoidosis

Materials and methods. 68 diagnosed sarcoidosis patients and 16 of apparently healthy individuals (control group) were examined before and after 3-month treatment. There were general clinical examination of patients with sarcoidosis perfomed, the levels of IL-2 and CRP were determined in bronchoalveolar fluid.

Results and discussion. In the control group, IL-2 ranged from 75,46±5,26 pg/l; CRP-1,61±0,17 mg/l. In patients with active pulmonary sarcoidosis prior to treatment IL-2 was 196,72±8,13 pg/l; CRP-28,34±2,45 mg/l. After 3 months of treatment the patients were divided into two groups: the success of therapy (group I) and treatment failure (group II). In the first group (n=47) a significant decrease in these parameters was determined: CRP-10,27±1,18 mg/l, IL-2-94,57±4,23pg/l. In Group II the inflammatory markers continued at high levels (IL-2-208,48±10,12 pg/L, CRP-31,86±2,64 pg/l).

Conclusion. Increased of IL-2 and CRP makes it possible to determine the effectiveness of the prescribed therapy and timely diagnose corticosteroid-resistance of pulmonary sarcoidosis for each patient.